人のウォール街のアナリストによると、ACRO Biomedical Co Ltdの収益見積もりは$から$の範囲です。
ACRO Biomedical Co Ltdの収益品質スコアはどれくらいですか?
ACRO Biomedical Co Ltdの収益品質スコアはB+/57.453953です。このスコアは、収益性、成長、キャッシュ生成と資本配分、レバレッジの4つの次元に基づいています。
ACRO Biomedical Co Ltdはいつ収益を報告しますか?
ACRO Biomedical Co Ltdの次の収益報告は2026-05-12に予定されています
ACRO Biomedical Co Ltdの予想収益はいくらですか?
ウォール街のアナリストによると、ACRO Biomedical Co Ltdの予想収益は$です。
ACRO Biomedical Co Ltdは収益予想を上回りましたか?
ACRO Biomedical Co Ltdの最近の収益は$で、予想を。
主要データ
前終値
$0.026
始値
$0.026
当日レンジ
$0.026 - $0.026
52週レンジ
$0.0222 - $0.1
取引高
66
平均取引高
610
配当利回り
--
1株当たり利益(TTM)
-0.00
時価総額
$1.5M
ACBMとは何ですか?
Acro Biomedical Co. Ltd. engages in the business of developing and marketing nutritional products that promote wellness and a healthy lifestyle. The company is headquartered in Fishers, Indiana. The company went IPO on 2016-06-23. The firm is focused on developing and marketing nutritional products that promote wellness and a healthy lifestyle. The firm's business consists of selling cordyceps related products that is used in traditional Chinese medicine. Cordyceps is a fungus which is a combination of a caterpillar and a fungus, which is found at altitudes above 4500 meters (m) in Sikkim. The firm is engaged in the purchase of products from three suppliers in Taiwan and the sale of these products to four unrelated customers. The company sells products in bulk to companies who may use the Company's products as ingredients in their products or sell the products they purchase from the Company to their own customers.